Cytokinetics, Incorporated
IT ˙ BIT ˙ US23282W6057
62,32 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1CYTK / Cytokinetics, Incorporated
InstitutionState Street Corp
Latest Disclosed Ownership5,617,334 shares
Ownership 4.70%
State Street Corp ownership in 1CYTK / Cytokinetics, Incorporated

2025-11-10 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,617,334 shares of Cytokinetics, Incorporated (IT:1CYTK). This represents 4.7 percent ownership of the company. In their previous filing dated 2024-01-25 , State Street Corp had reported owning 5,893,358 shares, indicating a decrease of -4.68 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-11-10 2025-11-10 13G 5,893,358 5,617,334 -4.68 4.70 -21.80
2024-01-25 2024-01-25 13G/A 5,044,914 5,893,358 16.82 6.01 12.76
2023-02-03 2023-02-03 13G/A 3,985,227 5,044,914 26.59 5.33 12.21
2022-02-09 2022-02-09 13G/A 4,640,923 3,985,227 -14.13 4.75 -27.59
2021-02-08 2021-02-08 13G 1,915,962 4,640,923 142.22 6.56 87.43
2019-02-12 2019-02-12 13G/A 2,715,972 1,915,962 -29.46 3.50 -30.56
2018-02-14 2018-02-14 13G 2,715,972 5.04

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CYTOKINETICS COM NEW 23282W605 5,745,193 -80,102 -1.38 378,666 2.30 0.0131
2026-02-13 2025-12-31 13F CYTOKINETICS COM NEW 23282W605 5,825,295 207,961 3.70 370,139 19.89 0.0124
2025-11-14 2025-09-30 13F CYTOKINETICS COM NEW 23282W605 5,617,334 -755,419 -11.85 308,729 46.63 0.0107
2025-08-14 2025-06-30 13F CYTOKINETICS COM NEW 23282W605 6,372,753 287,752 4.73 210,556 -13.90 0.0079
2025-05-15 2025-03-31 13F CYTOKINETICS COM NEW 23282W605 6,085,001 -82,339 -1.34 244,556 -15.70 0.0101
2025-02-14 2024-12-31 13F CYTOKINETICS COM NEW 23282W605 6,167,340 -290,984 -4.51 290,112 -14.92 0.0114
2024-11-14 2024-09-30 13F CYTOKINETICS COM NEW 23282W605 6,458,324 -90,212 -1.38 341,000 -3.89 0.0139
2024-08-14 2024-06-30 13F CYTOKINETICS COM NEW 23282W605 6,548,536 2,028,178 44.87 354,800 11.95 0.0155
2024-05-15 2024-03-31 13F CYTOKINETICS COM NEW 23282W605 4,520,358 -1,373,000 -23.30 316,922 -35.59 0.0142
2024-02-14 2023-12-31 13F CYTOKINETICS COM NEW 23282W605 5,893,358 618,872 11.73 492,036 216.65 0.0239
2023-11-14 2023-09-30 13F CYTOKINETICS COM NEW 23282W605 5,274,486 182,906 3.59 155,386 -6.44 0.0086
2023-08-14 2023-06-30 13F CYTOKINETICS COM NEW 23282W605 5,091,580 337,680 7.10 166,087 -0.72 0.0087
2023-05-15 2023-03-31 13F CYTOKINETICS COM NEW 23282W605 4,753,900 -291,014 -5.77 167,290 -27.63 0.0094
2023-05-15 2022-12-31 13F/A-99 CYTOKINETICS COM NEW 23282W605 5,044,914 789,789 18.56 231,158 12.12 0.0136
2023-05-15 2022-12-31 13F CYTOKINETICS COM NEW 23282W605 5,044,914 789,789 231,158 0.0136
2022-11-15 2022-09-30 13F CYTOKINETICS COM NEW 23282W605 4,255,125 -249,101 -5.53 206,161 16.49 0.0130
2022-08-15 2022-06-30 13F CYTOKINETICS COM NEW 23282W605 4,504,226 307,394 7.32 176,971 14.56 0.0106
2022-05-16 2022-03-31 13F CYTOKINETICS COM NEW 23282W605 4,196,832 211,605 5.31 154,485 -14.95 0.0076
2022-02-14 2021-12-31 13F CYTOKINETICS COM NEW 23282W605 3,985,227 -325,061 -7.54 181,647 17.91 0.0086
2021-11-15 2021-09-30 13F CYTOKINETICS COM NEW 23282W605 4,310,288 59,502 1.40 154,050 83.12 0.0081
2021-08-16 2021-06-30 13F CYTOKINETICS COM NEW 23282W605 4,250,786 108,816 2.63 84,123 -12.68 0.0044
2021-07-09 2021-03-31 13F/A-1 CYTOKINETICS COM NEW 23282W605 4,141,970 -498,953 -10.75 96,342 -0.10 0.0055
2021-05-17 2021-03-31 13F CYTOKINETICS COM NEW 23282W605 4,141,970 -498,953 96,342 0.0055
2021-02-16 2020-12-31 13F CYTOKINETICS COM NEW 23282W605 4,640,923 860,663 22.77 96,438 17.83 0.0059
2020-11-10 2020-09-30 13F CYTOKINETICS COM NEW 23282W605 3,780,260 739,228 24.31 81,843 14.18 0.0056
2020-08-14 2020-06-30 13F CYTOKINETICS COM NEW 23282W605 3,041,032 355,470 13.24 71,677 126.37 0.0052
2020-06-19 2020-03-31 13F/A-1 CYTOKINETICS COM NEW 23282W605 2,685,562 145,796 5.74 31,663 17.50 0.0028
2020-05-11 2020-03-31 13F CYTOKINETICS COM NEW 23282W605 2,685,562 145,796 31,663 2,780.6489
2020-02-06 2019-12-31 13F CYTOKINETICS COM NEW 23282W605 2,539,766 218,887 9.43 26,947 2.03 0.0018
2019-11-14 2019-09-30 13F CYTOKINETICS COM NEW 23282W605 2,320,879 -95,635 -3.96 26,412 -2.85 0.0020
2019-08-14 2019-06-30 13F CYTOKINETICS COM NEW 23282W605 2,416,514 374,437 18.34 27,186 64.56 0.0020
2019-05-15 2019-03-31 13F CYTOKINETICS COM NEW 23282W605 2,042,077 126,115 6.58 16,520 36.43 0.0013
2019-02-12 2018-12-31 13F CYTOKINETICS COM NEW 23282W605 1,915,962 -85,600 -4.28 12,109 -38.59 0.0011
2018-11-09 2018-09-30 13F CYTOKINETICS Common equity shares 23282W605 2,001,562 -43,739 -2.14 19,717 16.13 0.0015
2018-08-14 2018-06-30 13F CYTOKINETICS Common equity shares 23282W605 2,045,301 -316,311 -13.39 16,978 -0.16 0.0014
2018-05-15 2018-03-31 13F CYTOKINETICS Common equity shares 23282W605 2,361,612 -354,360 -13.05 17,005 -23.19 0.0014
2018-02-14 2017-12-31 13F CYTOKINETICS Common equity shares 23282W605 2,715,972 880,457 47.97 22,139 -16.82 0.0018
2017-11-14 2017-09-30 13F CYTOKINETICS Common equity shares 23282W605 1,835,515 161,180 9.63 26,615 31.37 0.0023
2017-08-14 2017-06-30 13F CYTOKINETICS Common equity shares 23282W605 1,674,335 741,909 79.57 20,259 69.09 0.0018
2017-05-15 2017-03-31 13F CYTOKINETICS Common equity shares 23282W605 932,426 34,678 3.86 11,981 9.84 0.0011
2017-02-09 2016-12-31 13F CYTOKINETICS Common equity shares 23282W605 897,748 -75,452 -7.75 10,908 22.07 0.0010
2017-01-13 2016-09-30 13F/A-1 CYTOKINETICS Common equity shares 23282W605 973,200 349,954 56.15 8,936 51.18 0.0009
2016-11-14 2016-09-30 13F CYTOKINETICS Common equity shares 23282W605 973,200 8,936
2016-08-12 2016-06-30 13F CYTOKINETICS Common equity shares 23282W605 623,246 77,786 14.26 5,911 53.73 0.0006
2016-05-20 2016-03-31 13F/A-1 CYTOKINETICS Common equity shares 23282W605 545,460 -255,751 -31.92 3,845 -54.12 0.0004
2016-05-12 2016-03-31 13F CYTOKINETICS Common equity shares 23282W605 545,460 3,845
2016-02-16 2015-12-31 13F CYTOKINETICS Common equity shares 23282W605 801,211 250,173 45.40 8,380 127.16 0.0009
2015-11-16 2015-09-30 13F CYTOKINETICS Common equity shares 23282W605 551,038 1,423 0.26 3,689 -0.14 0.0004
2015-08-13 2015-06-30 13F CYTOKINETICS Common equity shares 23282W605 549,615 14,282 2.67 3,694 1.79 0.0004
2015-05-15 2015-03-31 13F CYTOKINETICS Common equity shares 23282W605 535,333 26,166 5.14 3,629 -11.03 0.0004
2015-02-11 2014-12-31 13F CYTOKINETICS Common equity shares 23282W605 509,167 5,677 1.13 4,079 129.54 0.0004
2014-11-12 2014-09-30 13F/A-1 CYTOKINETICS Common equity shares 23282W605 503,490 10,122 2.05 1,777 -24.70 0.0002
2014-11-10 2014-09-30 13F CYTOKINETICS Common equity shares 23282W605 503,490 1,777
2014-08-12 2014-06-30 13F CYTOKINETICS Common equity shares 23282W605 493,368 4,194 0.86 2,360 -49.23 0.0003
2014-05-15 2014-03-31 13F/A-1 CYTOKINETICS Common equity shares 23282W605 489,174 76,964 18.67 4,648 73.63 0.0005
2014-05-13 2014-03-31 13F CYTOKINETICS Common equity shares 23282W605 489,474 4,651
2014-02-06 2013-12-31 13F/A-1 CYTOKINETICS Common equity shares 23282W605 412,210 34,523 9.14 2,677 -6.69 0.0003
2014-02-06 2013-12-31 13F CYTOKINETICS Common equity shares 23282W605 35,722 24
2013-11-12 2013-09-30 13F CYTOKINETICS Common Stock 23282W605 377,687 88,953 30.81 2,869 -14.10 0.0004
2013-08-08 2013-06-30 13F CYTOKINETICS Common Stock 23282W605 288,734 288,734 3,340 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.